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Increased resistance to antimicrobials in clinically important bacteria has been widely reported. -e major mechanism causing
multidrug resistance (MDR) is mediated by efflux pumps, proteins located in the cytoplasmic membrane to exclude antimicrobial
drug. Some efflux pumps recognize and expel a variety of unrelated antimicrobial agents, while other efflux pumps can expel only
one specific class of antibiotics. Previously, we have reported that xylose decreases the efflux-mediated antimicrobial resistance in
Salmonella typhimurium, Pseudomonas aeruginosa, and Acinetobacter baumannii in vitro. In this work, we assessed the ef-
fectiveness of combining xylose with antibiotics to kill resistant Acinetobacter baumannii and Klebsiella pneumoniae in a murine
model of skin infection. Skin infections were established by seeding 109 bacteria onto eroded skin of mice. Mice treated with the
antibiotic alone or with a mixture of glucose and antibiotics or xylose and antibiotics were compared to a control group that was
infected but received no further treatment. We observed that the mixtures xylose-tetracycline and xylose-chloramphenicol
produced a decrease of at least 10 times viable Acinetobacter baumannii and Klebsiella pneumoniae recovered from infected skin,
compared with mice treated with the antibiotic alone. Our results show that xylose improves the antibiotic activity of tetracycline
and chloramphenicol against efflux-mediated resistance Acinetobacter baumannii and Klebsiella pneumoniae, in a murine model
of skin infection. We envision these combined formulations as an efficient treatment of skin infections with bacteria presenting
efflux-mediated resistance, in both humans and animals.
1. Introduction
Skin infections are one of the most common infections [1].
Breaks in the skin, such as leg ulcers and surgical or traumatic
wounds, constitute a perfect environment for infections by
a broad range of bacteria [2]. Most skin infections are caused
by Gram-positive bacteria, commonly Staphylococcus aureus
and group A β-haemolytic Streptococcus [1].However, Gram-
negative bacteria such as Acinetobacter baumannii, Pseudo-
monas aeruginosa, and Klebsiella pneumoniae may also cause
skin infections [2]. -e incidence of skin infections has in-
creased due to ageing of the general population, increased
number of critically ill patients, increased number of im-
munocompromised patients, and recent emergence of
multidrug-resistant pathogens [3]. Multidrug resistance
(MDR) is defined as the resistant phenotype to antibiotics
belonging to two or more classes of antibiotics and represents
a serious problem in healthcare settings [4, 5]. Drug-resistant
bacteria are responsible for more than 30,000 deaths per year
in the UK and Europe, and it is estimated that 23,000 people
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in the United States die from pathogens that are not re-
sponsive to treatments with current antibiotic therapies [6].
Bacteria exhibit different strategies to resist antibiotics.
One of the most important mechanisms, considered a major
contributor to the emergence of MDR pathogens, is the
antibiotic efflux achieved by efflux pumps [7]. Efflux pumps
are proteins located in the inner membrane of Gram-
negative bacteria and in the cytoplasmic membrane of
Gram-positive bacteria [7].-e continuous onset of MDR in
bacterial strains limits the clinical efficacy of most available
antibiotics. -erefore, there is an urgent need to introduce
novel antimicrobial molecules that may be active by
themselves or potentiate current available antibiotics [8].
In a previous in vitro study, we found that xylose de-
creases the efflux-mediated antimicrobial resistance in
S. typhimurium, P. aeruginosa, and A. baumannii. Although
the mechanism behind sensitization remains elusive, it has
been speculated that either competitions for limited space in
the inner membrane or interference with the translocon sys-
tems may affect translocation of efflux pumps into membrane,
thereby affecting efflux-mediated resistance [9]. Because the in
vitro potentiation of actively expelled antimicrobials was fairly
significant in the presence of xylose, we ought to find whether
this potentiation can be reproduced in vivo. -erefore, in this
work, we assessed the effectiveness of combining xylose with
antibiotics in vivo. Our results show that xylose increases the
antibiotic activity of tetracycline and chloramphenicol against
efflux-dependent resistant A. baumannii and K. pneumoniae,
in a model of skin infection in mice.
2. Materials and Methods
2.1. Bacterial Strains andGrowthConditions. Clinical strains
of A. baumannii and K. pneumoniae were collected from
different healthcare facilities throughout Santiago, Chile,
and collected at Servicio de Laboratorios Cl´ınicos, Escuela de
Medicina, Pontificia Universidad Cato´lica de Chile in
Santiago, between 2014 and 2015. -e A. baumannii strains
were isolated from tracheal secretions from patients with
respiratory infection. -e K. pneumoniae strains were iso-
lated from urine of patients with urinary infection. Strains
were grown in LB broth at 37°C with aeration. Solid media
(LB agar) included Bacto agar (15 g/L).
2.2. Antimicrobial Susceptibility Test. We used a modifica-
tion of the disc diffusion assay previously described [9, 10].
Briefly, cultures were grown for 16 h in LB broth; bacteria
were washed three times and resuspended in PBS. 106 cells
were spread on M9 plates supplemented with glucose or
xylose (2mg/mL) [9]. When required, the medium
was supplemented with 12.5 μM carbonyl cyanide-m-
chlorophenylhydrazone (CCCP), an indirect efflux pumps
inhibitor that acts by impairing the proton transport. Ten
microliters of tetracycline 10 μg/mL or chloramphenicol
20 μg/mL were spotted in a sterile filter paper disc, placed on
the center of the plate. -e diameters of the inhibition
haloes, obtained after an overnight culture at 37°C, were
reported as the average of two measurements.
-e MICs for each bacterial strain were determined by
microdilution in liquid medium as recommended by the CLSI
[11], with modifications. Briefly, bacteria were grown over-
night in LBmedium, washed 3 times with PBS, diluted in fresh
M9 glucose medium or M9 xylose medium, and aliquoted
(100μL) into the wells of sterile microtitre plates (106CFU/mL
in each well).-e lowest concentration of antimicrobial agents
that inhibited growth (measured as the optical density at
640 nm) by at least 50%, relative to growth in the absence of
antimicrobial agents, was defined as the MIC. When required,
the medium was supplemented with 12.5 μM CCCP.
2.3. Skin Infections. Female BALB/c mice (7–8 weeks old)
were anesthetized with a mixture of 1 : 3 of xylazine 2% and
ketamine 115mg/mL intraperitoneally injected (1 µL per g of
weight). Followed by this, 1 cm2 of skin was shaved, on the
back of each animal, to produce a slight irritation. -e area
was immediately infected with 20 µL of a PBS-bacterial
suspension containing 1× 109 CFU/mL of A. baumannii
or K. pneumoniae. Littermate mice were distributed into
four groups: the control group, which was only infected but
received no further treatment; the antibiotic-treated group,
which was treated topically with 20 µL of antibiotics (tet-
racycline 2.5 μg/mL when A. baumannii was used or
chloramphenicol 2.5 μg/mL when K. pneumoniae was used);
and the glucose-antibiotic group and the xylose-antibiotic
group, which were treated topically with a mixture of 20 µL
of 2.5 μg/mL antibiotic (tetracycline or chloramphenicol)
plus 20 µL of sugar (glucose 2% or xylose 2%). -e treat-
ments started 4 h after infection and were repeated every
12 h. -ree days after infection, mice were euthanized to
dissect 1 cm2 of the infected areas, which were homogenized
in 0.5mL of PBS to obtain the CFU by plating onto LB agar.
Bacterial recovered from the infected skin were confirmed as
A. baumannii or K. pneumoniae by using API10s test. Ex-
periments with animals were performed according to Pro-
tocol 012-2013 approved by the Bioethics Committee at
Universidad Andre´s Bello and in accordance with the NIH
guide for the care and use of laboratory animal.
3. Results
3.1. 5e Presence of Xylose Decreased the Efflux-Pump-
Mediated Antimicrobial Resistance in A. baumannii and
K. pneumoniae. In a previous study, we determined that
xylose, as the sole carbon source, decreases efflux-mediated
resistance of Gram-negative bacteria to different antibiotics in
vitro [9]. Since A. baumannii and K. pneumoniae are fre-
quently resistant to tetracycline and chloramphenicol by
mechanisms involving efflux pumps [12, 13], in this study we
used these antibiotics to test the effect of xylose. In the in
vitro experiments, we observed that 60% (9/15) of the
A. baumannii strains tested increased their susceptibility to
tetracycline when xylose was the sole carbon source (Sup-
plementary Table S1). Similarly, 77% (10/13) of tested
K. pneumoniae strainsweremore susceptible to chloramphenicol
when xylose was the sole carbon source (Supplementary
Table S1). To study how xylose may affect efflux-dependent
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resistance, we choose two strains of A. baumannii (34702
and 34280) and two strains of K. pneumoniae (28296 and
28341) to perform the in vitro and in vivo experiments. In
Table 1, we show that A. baumannii 34702 and K. pneu-
moniae 28296 exhibited efflux-dependent resistance (EDR) to
tetracycline or chloramphenicol, respectively, as assessed by
the increased susceptibility in presence of the efflux pump
inhibitor CCCP [9, 14]. It has been reported that resistance in
A. baumannii to tetracycline is attained by expelling the drug
mainly through the AedC, CraA, AdeB, AdeG, and AdeJ
efflux pumps [12,15–17]. Similarly, in K. pneumoniae, the
resistance to chloramphenicol is attained by expelling the
drug mainly through the AcrB efflux pump [18]. By contrast,
A. baumannii 34280 andK. pneumoniae 28341 showed efflux-
independent resistance (EIR) to tetracycline or chloram-
phenicol, respectively, since the presence of CCCP exerted no
effect in the growth inhibition haloes. Furthermore, the
presence of xylose as the sole carbon source increased the
antibiotic susceptibility only in the EDR strains (Table 1). To
quantitatively confirm our results, we performed MIC assay
for each bacterial strain. As observed in Table 1, the MIC for
tetracycline in A. baumannii 34702 was 2 μg/mL in presence
of xylose, compared with 64 μg/mL in the presence of glucose;
therefore, the same strain was 32 times more susceptible to
tetracycline in presence of xylose. In the same way, the results
observed for K. pneumoniae 28296 showed that the MIC for
chloramphenicol was 2 μg/mL in the presence of xylose,
comparedwith 32 μg/mL in the presence of glucose; therefore,
the same strain was 16 times more susceptible to chloram-
phenicol in the presence of xylose. -ese results confirm that
both strains exhibited efflux-dependent resistance (EDR) to
tetracycline or chloramphenicol, respectively.
As a control, we performed a growth curve for
A. baumannii 34702 and K. pneumoniae 28296 with glucose
or xylose as the sole carbon source to determine the bacterial
growth rate.-e results in Figure S1 (in supplementary data)
show that the growth rate of A. baumannii 34702 in xylose is
slightly lower than that in the presence of glucose, as the sole
carbon source (in logarithmic phase: A. baumannii+Glu:
0.18 h−1 and A. baumannii+Xyl: 0.17 h−1). A similar result
was observed in K. pneumoniae 28296 (in logarithmic phase:
K. pneumoniae+Glu: 0.19 h−1 and K. pneumoniae+Xyl:
0.16 h−1) (Figure S2 in supplementary data). Notwith-
standing the lower growth rate in minimal medium plus
xylose, the growth inhibition haloes were evident for both
A. baumannii and K. pneumoniae in the presence of either
tetracycline or chloramphenicol. In addition, the inhibition
haloes measured after 12 h remained unmodified when
measured after 24, 48, or 72 h (Tables S2 and S3, included in
supplementary data). -us, we conclude that xylose affects
resistance to tetracycline or chloramphenicol independently
from its effects on growth rates. -ese results strongly
suggest that both strains exhibit efflux-dependent resistance
(EDR) to tetracycline or chloramphenicol, respectively.
As expected, A. baumannii 34280 and K. pneumoniae
28341, both showing efflux-independent resistance (EIR) to
tetracycline or chloramphenicol, presented no changes in
the MIC, whether cultured in the presence of xylose or
glucose as the sole carbon source (Table 1). In addition, the
presence of CCCP exerted no effect on the MIC (Table 1,
glucose versus glucose +CCCP). In our experiments, we
used CCCP at concentrations ranging from 4 to 10 times less
than used in previous reports [19, 20]. Furthermore, we
assessed the growth of A. baumannii 34702 and K. pneu-
moniae 28296 in presence or absence of CCCP (12.5 μM).
-e results in Figures S1 and S2 (supplementary data) show
that CCCP does not affect the growth rate of A. baumannii
34702 (in logarithmic phase: A. baumannii+Glu: 0.18 h−1
and A. baumannii+Glu +CCCP: 0.33 h−1) or K. pneumo-
niae 28296 (in logarithmic phase: K. pneumoniae+Glu:
0.19 h−1 and K. pneumoniae+Glu +CCCP: 0.14 h−1).
Altogether, these in vitro experiments show that xylose
potentiated the antibiotic activity of tetracycline and
chloramphenicol in EDR strains of A. baumannii and
K. pneumoniae.
3.2. Xylose Potentiates the Antibiotic Activity of Tetracycline
and Chloramphenicol against EDR Strains of A. baumannii
and K. pneumoniae in a Murine Model of Skin Infection.
To determine whether xylose can potentiate antibiotic ac-
tivity, not only in vitro but also in vivo, a murine model of
skin infection was chosen using the same strains and an-
tibiotics described in Table 1. Skin infections were estab-
lished by seeding A. baumannii or K. pneumoniae on the
skin of mice, previously shaved to generate lesions, as
previously described in method sections and in references
[18]. Bacteria recovered from the infected skin and treated
with the antibiotics or with a mixture of glucose and an-
tibiotics or xylose and antibiotics were compared with
a control group that was infected but received no further
treatment. As shown in Figure 1(a), we recovered 10 times
less CFU of A. baumannii 34702 (EDR strain) from
tetracycline-treated mice than from the untreated group. In
addition, we observed that the mixture of xylose and tet-
racycline was the most efficient treatment, decreasing the
recovery of A. baumannii 34702 100 times compared with
the untreated control mice and 10 times compared with the
tetracycline-treated mice. Control group of infected mice
treated with xylose alone and mice treated with a mixture of
Table 1: Susceptibility profile of A. baumannii and K. pneumoniae strains used in a model of skin infection in mice.
Strains Resistance Antibiotics
Inhibition halo (mm) MIC (μg/mL)
Glu Xyl Glu +CCCP Glu Xyl Glu +CCCP
A. baumannii 34702 EDR Tet 45 50 52 64 2 32
A. baumannii 34280 EIR Tet 45 45 44 64 64 64
K. pneumoniae 28296 EDR Cam 39 49 48 32 2 16
K. pneumoniae 28341 EIR Cam 13 15 15 8 8 8
Canadian Journal of Infectious Diseases and Medical Microbiology 3
glucose and tetracycline showed no dierences in the bac-
terial count, compared to untreated control group and
antibiotic-treated group, respectively. Importantly, the ad-
dition of xylose did not improve the eect of tetracycline in
mice infected with A. baumannii 34280, an EIR strain, as
expected from our in vitro assays (Figure 1(b)).
We obtained similar results with K. pneumoniae, where
xylose clearly improved the eect of chloramphenicol only
in K. pneumoniae 28296 (300 times compared to the re-
covered CFU from untreated mice and 30 times compared to
the antibiotic-treated group), an EDR strain, but not in
K. pneumoniae 28341, an EIR strain (Figures 1(c) and 1(d)).
A control group of infectedmice treated with xylose alone and
mice treated with a mixture of glucose and chloramphenicol
showed no dierences in the bacterial count. Again, these
results are consistent with those obtained in vitro (Table 1).
As a control, we grew A. baumannii 34702 and K. pneu-
moniae 28296 in the presence of dierent concentrations
of xylose. Our observations did not show impaired growth or
antibacterial eect of this sugar alone against bacteria
(Table S4 in supplementary data).
4. Discussion
e data presented show that xylose can be used to potentiate
the antibiotic activity of tetracycline and chloramphenicol in
vivo in strains presenting EDR. For this study, we have chosen
tetracycline and chloramphenicol, antibiotics which re-
sistance is commonly achieved through eux pumps. e
antibiotic tetracycline is still used against both Gram-positive
and Gram-negative bacteria. Although tetracycline is not the
rst choice against skin infections because it can cause
phototoxic reactions [21], it is useful in several other types of
infections, including rickettsial, chlamydial and periodontal
infections, and atypical pneumonias [22]. Considering that
tetracycline resistance easily arises because of horizontal gene
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Figure 1: Xylose potentiates antibiotic activity of eux-dependent resistant bacteria in a murine model of skin infection. e ability of
xylose to increase the susceptibility of clinical A. baumannii and K. pneumomiae strains to tetracycline and chloramphenicol, respectively,
was determined in vivo. Bacteria were used to infect skin lesion in mice, prior to treating mice with the antibiotic alone or with a mixture of
the antibiotic and xylose. As control, a group of mice was treated with antibiotic and glucose, while another was left untreated. We tested the
EDR strain A. baumannii 34702 (a) and the EIR strain A. baumannii 34280 (b) with tetracycline; and the EDR strain K. pneumomiae 28296
(c) and the EIR strain K. pneumomiae 28341 (d) with chloramphenicol. Results are expressed as CFU/mL of homogenized tissue. Ex-
periments were repeated at least 3 times. ∗p< 0.05 and ∗∗p< 0.01 according to Student’s t-test.
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transfer encoding efflux systems, the results described in this
manuscript may have a major impact on the treatment of
tetracycline-resistant bacteria.
Chloramphenicol presents excellent in vitro activity
against most anaerobes, which are a major cause of skin
infections [23]. -erefore, the evidence presented here sug-
gests that adding xylose to antibiotics from different families is
useful for increasing the antimicrobial effect of antibiotics that
show prevalence for resistance through active efflux. In
a previous work, we hypothesized that it is possible to alter the
efflux pump-mediated antibiotic resistance by overproducing
unrelated inner membrane proteins, such as carbohydrate
permeases. An easy way to increase the production of per-
meases is to culture bacteria with a non-PTS carbohydrate as
the sole carbon source, such as xylose. Indeed, xylose was the
best non-PTS sugar at potentiating antibiotic effects, com-
pared to galactose or arabinose [9]. In addition, xylose was
chosen because it is apparently innocuous, and its
pharmacokinetic/pharmacodynamics parameters have been
extensively studied. Indeed, xylose is administered systemi-
cally at high doses to assess intestinal absorption in human.
In a next step, we will incorporate various excipients to the
mixture of antibiotic and xylose to enhance the effect as part
of a topic formulation. Importantly, and beside our pre-
dictions, wound exudates, whichmay contain glucose, a sugar
that exerts catabolic repression over xylose metabolism
(Table S5 in supplementary data) apparently did not inhibit
the in vivo effects of xylose regarding antibiotic sensitization.
5. Conclusion
In summary, the data we presented here demonstrate that
xylose potentiates the in vivo antibiotics effect of tetracycline
and chloramphenicol in bacteria that actively expel these
antibiotics. Such effect was previously demonstrated in vitro
for tetracycline and chloramphenicol, both actively expelled
antibiotics. In addition, we show evidence that xylose is ef-
fective in potentiating antibiotic activity of tetracycline and
chloramphenicol besides glucose present on wound exudates.
-ese results are not only a proof of principles but also ground
to expand the use of xylose with two purposes: uncovering
EDR mechanisms and potentiating susceptibility of bacteria
showing EDR, to antibiotics tested in this study and others.
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